Tech Company Financing Transactions

Calidi Biotherapeutics Funding Round

Calidi Biotherapeutics closed a $25 million Series B funding round on 6/23/2023. Investors included Calidi Cure, private investors and Jackson Investment Group.

Transaction Overview

Announced On
6/23/2023
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Proceeds Purpose
Calidi's technology utilizing stem cells to deliver and potentiate oncolytic viruses is a novel and differentiated approach to fighting cancer. I am grateful to our new and existing investors for their support of our mission and look forward to using this funding to continue pushing the frontiers of stem cells and oncolytic viral therapies and making a difference in the lives of patients.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10210 Campus Point Dr. 150
San Diego, CA 92121
USA
Email Address
Overview
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the utilization of oncolytic viruses through an allogeneic cell-based delivery system. Calidi Biotherapeutics is advancing this potent stem cell and oncolytic virus (SN-V1c-vaccinia virus) combination for use in multiple difficult-to-treat oncology indications.
Profile
Calidi Biotherapeutics LinkedIn Company Profile
Social Media
Calidi Biotherapeutics Company Twitter Account
Company News
Calidi Biotherapeutics News
Facebook
Calidi Biotherapeutics on Facebook
YouTube
Calidi Biotherapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Allan Camaisa
  Allan Camaisa LinkedIn Profile  Allan Camaisa Twitter Account  Allan Camaisa News  Allan Camaisa on Facebook
Chief Medical Officer
Boris Minev
  Boris Minev LinkedIn Profile  Boris Minev Twitter Account  Boris Minev News  Boris Minev on Facebook
Vice President
Dobrin Draganov
  Dobrin Draganov LinkedIn Profile  Dobrin Draganov Twitter Account  Dobrin Draganov News  Dobrin Draganov on Facebook
VP - Bus. Development
Stephen Keane
  Stephen Keane LinkedIn Profile  Stephen Keane Twitter Account  Stephen Keane News  Stephen Keane on Facebook
VP - Operations
Stephen Thesing
  Stephen Thesing LinkedIn Profile  Stephen Thesing Twitter Account  Stephen Thesing News  Stephen Thesing on Facebook
VP - R & D
Antonio Santidrian
  Antonio Santidrian LinkedIn Profile  Antonio Santidrian Twitter Account  Antonio Santidrian News  Antonio Santidrian on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/23/2023: PM Pediatrics venture capital transaction
Next: 6/23/2023: Continuum Space Systems venture capital transaction

 

Share this article

 


Where The Data Comes From

We document funding rounds that are announced publicly. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary